Human Telomerase Gene and High-Risk Human Papillomavirus Infection are Related to Cervical Intraepithelial Neoplasia

  • Zhao, Xu-Ye (Department of Gynecology and Obstetrics, Chinese PLA General Hospital & Chinese PLA Medical School) ;
  • Cui, Yongm (Department of Pathophysiology, Binzhou Medical University) ;
  • Jiang, Shu-Fang (Department of Gynecology and Obstetrics, Chinese PLA General Hospital & Chinese PLA Medical School) ;
  • Liu, Ke-Jun (Department of Gynecology and Obstetrics, Chinese PLA General Hospital & Chinese PLA Medical School) ;
  • Han, Hai-Qiong (Department of Gynecology, Shanxi Tumor Hospital) ;
  • Liu, Xiao-Su (Department of Gynecology, Shanxi Tumor Hospital) ;
  • Li, Yali (Department of Gynecology and Obstetrics, Chinese PLA General Hospital & Chinese PLA Medical School)
  • Published : 2015.02.25


Our aims were to evaluate the clinical performance of human telomerase RNA gene component (hTERC gene) amplification assay with high-risk human papillomavirus (HR-HPV) DNA test of Hybrid Capture 2 DNA test (HC2), for the detection of high grade cervical precancerous lesions and cancer (CIN 2+). In addition, the association shown between hTERC gene amplification and HPV DNA test positive in women with and without cervical neoplasia was assessed. There were 92 women who underwent cytology, HR-HPV DNA test, hTERC gene amplification test, colposcopy and biopsy. We compared the clinical performance of hTERC gene test along with HR-HPV DNA test of women with colposcopy and routine screening. The samples were histology-confirmed high-grade cervical intraepithelial neoplasia (CIN 2) or worse (CIN2+) as the positive criterion. The test of hTERC gene showed the hTERC gene amplification positivity increased with the severity of histological abnormality and cytological abnormality. The test of hTERC gene showed higher specificity than HR-HPV DNA test for high-grade lesions (84.4% versus 50%) and also higher positive predictive value (90.4% versus 76.5%). Our results predicted that hTERC gene amplification demonstrated more specific performance for predicting the risk of progression and offer a strong potential as a tool for triage in cervical cancer screening, with the limited sensitive as HR-HPV DNA test.


Supported by : Chinese People's Liberation Army General Hospital


  1. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al (2010). Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ, 340, 1804.
  2. Baussano I, Ronco G, Segnan N, et al (2010). HPV-16 infection and cervical cancer: modeling the influence of duration of infection and precancerous lesions. Epidemics, 2, 21-8.
  3. Caraway NP, Khanna A, Dawlett M, et al (2008). Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma. Gynecol Oncol, 110, 37-42.
  4. Chen Q, Wang X, Ru Y, et al (2011). Amplification of the telomerase RNA component gene in the process of human esophageal carcinogenesis. Tohoku J Exp Med, 224, 99-104.
  5. Chen SM, Lin W, Liu X, et al (2012). Significance of human telomerase RNA gene amplification detection for cervical cancer screening. Asian Pac J Cancer Prev, 13, 2063-8.
  6. Costa C, Espinet B, Molina MA, et al (2009). Analysis of gene status in cervical dysplastic lesions and squamous cell carcinoma using tissue microarrays. Histol Histopathol, 24, 821-9.
  7. Ekeowa-Anderson AL, Purdie KJ, Gibbon K, et al (2012). AKT1 loss correlates with episomal HPV16 in vulval intraepithelial neoplasia. PLoS One, 7, 38608.
  8. Hopman AH, Theelen W, Hommelberg PP, et al (2006). Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J Pathol, 210, 412-9.
  9. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  10. Jing L, Zhong X, Huang W, et al (2014). HPV genotypes and associated cervical cytological abnormalities in women from the Pearl River Delta region of Guangdong province, China: a cross-sectional study. BMC Infect Dis, 14, 388.
  11. Kirchhoff M, Rose H, Petersen BL, et al (2001). Comparative genomic hybridization reveals non-random chromosomal aberrations in early preinvasive cervical lesions. Cancer Genet Cytogenet, 129, 47-51.
  12. Liu H, Liu S, Wang H, et al (2012). Genomic amplification of the human telomerase gene (hTERC) associated with human papillomavirus is related to the progression of uterine cervical dysplasia to invasive cancer. Diagn Pathol, 7, 147.
  13. Moscicki AB, Schiffman M, Kjaer S, et al (2006). Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine, 24, 42-51.
  14. Oikonomou P, Mademtzis I, Messinis I, et al (2006). Quantitative determination of human telomerase reverse transcriptase messenger RNA expression in premalignant cervical lesions and correlation with human papillomavirus load. Hum Pathol, 37, 135-42.
  15. Pett MR, Herdman MT, Palmer RD, et al (2006). Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proc Natl Acad Sci U S A, 103, 3822-7.
  16. Sui W, Ou M, Dai Y, et al (2009). Gain of the human telomerase RNA gene TERC at 3q26 is strongly associated with cervical intraepithelial neoplasia and carcinoma. Int J Gynecol Cancer, 19, 1303-6.
  17. Szarewski A, Ambroisine L, Cadman L, et al (2008). Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev, 17, 3033-42.
  18. Trope A, Sjoborg K, Eskild A, et al (2009). Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J Clin Microbiol, 47, 2458-64.
  19. Van Doorslaer K, Burk RD (2012). Association between hTERT activation by HPV E6 proteins and oncogenic risk. Virology, 433, 216-9.
  20. Wang YF, Wang XS, Gao SG, et al (2013). Clinical significance of combined detection of human papilloma virus infection and human telomerase RNA component gene amplification in patients with squamous cell carcinoma of the esophagus in northern China. Eur J Med Res, 18, 11.
  21. Wilting SM, Snijders PJ, Verlaat W, et al (2013). Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene, 32, 106-16.
  22. Zhang Y, Wang X, Ma L, et al (2009). Clinical significance of hTERC gene amplification detection by FISH in the screening of cervical lesions. J Huazhong Univ Sci Technolog Med Sci, 29, 368-71.
  23. Zheng PS, Iwasaka T, Zhang ZM, et al (2000). Telomerase activity in Papanicolaou smear-negative exfoliated cervical cells and its association with lesions and oncogenic human papillomaviruses. Gynecol Oncol, 77, 394-8.

Cited by

  1. 'Drawing' a Molecular Portrait of CIN and Cervical Cancer: a Review of Genome-Wide Molecular Profiling Data vol.16, pp.11, 2015,
  2. Telomeres and Telomerase During Human Papillomavirus-Induced Carcinogenesis vol.22, pp.4, 2018,